Skip to main content
Premium Trial:

Request an Annual Quote

BC Platforms, Blueprint Genetics Partner on Data-Driven Clinical Genetic Testing

NEW YORK – BC Platforms said today that it has entered into a collaboration with Finnish company Blueprint Genetics to develop data-driven clinical genetic testing services for patients with rare diseases.

The partners will combine Blueprint Genetics' clinical genetic testing services with BC Platforms' data management technology to help hospital systems and life sciences companies incorporate large genetic datasets into patient care, research studies, and sponsored testing programs, they said.

Zurich, Switzerland-based BC Platforms, which also has R&D operations in Finland, and Blueprint Genetics will build a virtual center of excellence to support the integration of genetic testing and clinical data applications, they said. According to the companies, this platform will support efficient delivery of test results and related health information in hopes of improving patient care.

"We believe that together we can provide a highly competitive platform and a one-stop shop for genetic testing and data management to help patients suffering from rare inherited diseases," BC Platforms CEO Tero Silvola said in a statement.

"Linking our high-quality genetic testing with BC Platforms' data management capabilities allows us to improve patient outcomes, reduce operating costs in healthcare organizations, and speed up the time to discovery," added Blueprint Genetics CEO Tommi Lehtonen.

Two weeks ago, Blueprint Genetics announced that it would open a testing lab in North America to meet growing demand for its sequencing-based rare disease gene panels. The new lab will offer both NGS-based panels and biochemical tests, which Blueprint is bringing in house through a partnership with Austrian firm Archimedlife Medical Laboratory.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.